Patents Assigned to International Institute of Cancer Immunology, Inc.
-
Publication number: 20140134200Abstract: An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided.Type: ApplicationFiled: December 26, 2013Publication date: May 15, 2014Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo SUGIYAMA
-
Patent number: 8653038Abstract: An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence cons sting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided.Type: GrantFiled: December 14, 2007Date of Patent: February 18, 2014Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Publication number: 20140046036Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: ApplicationFiled: September 10, 2013Publication date: February 13, 2014Applicants: International Institute of Cancer Immunology, Inc., Dainippon Sumitomo Pharma Co., Ltd., Chugai Seiyaku Kabushiki KaishaInventors: Toshio NISHIHARA, Masashi Gotoh
-
Publication number: 20140023670Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.Type: ApplicationFiled: June 18, 2013Publication date: January 23, 2014Applicant: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventor: Haruo SUGIYAMA
-
Patent number: 8557779Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.Type: GrantFiled: December 5, 2008Date of Patent: October 15, 2013Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Publication number: 20130266958Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1* 0101 molecule, an HLA-DRB1* 0401 molecule, an HLA-DRB1* 0403 molecule, an HLA-DRB1* 0406 molecule, an HLA-DRB1* 0803 molecule, an HLA-DRB1* 0901 molecule, an HLA-DRB1* 1101 molecule, an HLA-DRB3* 0202 molecule, an HLA-DRB4* 0101 molecule, an HLA-DPB1* 0201 molecule or an HLA-DPB1* 0301 molecule, and the like.Type: ApplicationFiled: October 4, 2011Publication date: October 10, 2013Applicants: OTSUKA PHARMACEUTICAL CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INCInventors: Haruo Sugiyama, Shinji Sogo, Masayoshi Sato, Ryuki Kitamoto, Yoshihiro Goto
-
Publication number: 20130243800Abstract: The present invention provides a method of treating or preventing cancer, by administering a peptide consisting of 16-25 contiguous amino acids in the amino acid sequence of human WT1 of SEQ ID NO: 1, which has the amino acid sequence of SEQ ID NO: 24, an expression vector having a polynucleotide encoding said peptide or a cell containing the expression vector to a subject in need thereof.Type: ApplicationFiled: January 31, 2013Publication date: September 19, 2013Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo SUGIYAMA
-
Publication number: 20130225502Abstract: The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide.Type: ApplicationFiled: October 31, 2012Publication date: August 29, 2013Applicant: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventor: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
-
Publication number: 20130196427Abstract: The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide.Type: ApplicationFiled: January 24, 2013Publication date: August 1, 2013Applicant: International Institute of Cancer Immunology, Inc.Inventor: International Institute of Cancer Immunology, Inc.
-
Patent number: 8388975Abstract: The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide.Type: GrantFiled: September 4, 2009Date of Patent: March 5, 2013Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 8288355Abstract: Disclosed is a polynucleotide having at least 15 contiguous bases in the base sequence of SEQ ID NO:26 and including the base sequence of SEQ ID NO:27. Also disclosed is siRNA produced based on the polynucleotide. By means of this, a cancer cell-specific molecular-targeted therapy, which successfully controls the function of WT1, can be realized.Type: GrantFiled: March 28, 2007Date of Patent: October 16, 2012Assignee: International Institute of Cancer Immunology, Inc.Inventors: Haruo Sugiyama, Yusuke Oji
-
Patent number: 8242084Abstract: The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.Type: GrantFiled: June 7, 2010Date of Patent: August 14, 2012Assignees: Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.Inventors: Haruo Sugiyama, Hideo Takasu, Fumio Samizo
-
Patent number: 8105604Abstract: The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its active ingredient, and a DNA vaccine having for its active ingredient DNA that codes for this peptide.Type: GrantFiled: September 2, 2009Date of Patent: January 31, 2012Assignee: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Publication number: 20110229506Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: ApplicationFiled: March 22, 2011Publication date: September 22, 2011Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: TOSHIO NISHIHARA, MASASHI GOTOH
-
Publication number: 20110070251Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.Type: ApplicationFiled: December 5, 2008Publication date: March 24, 2011Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo Sugiyama
-
Patent number: 7807792Abstract: A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.Type: GrantFiled: February 5, 2009Date of Patent: October 5, 2010Assignee: International Institute of Cancer Immunology, Inc.Inventors: Haruo Sugiyama, Yoshihiro Oka
-
Publication number: 20100190163Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.Type: ApplicationFiled: February 28, 2008Publication date: July 29, 2010Applicant: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventor: Haruo Sugiyama
-
Publication number: 20100062010Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: ApplicationFiled: November 29, 2006Publication date: March 11, 2010Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: Toshio Nishihara, Masashi Gotoh
-
Publication number: 20100062013Abstract: The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide.Type: ApplicationFiled: September 4, 2009Publication date: March 11, 2010Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo SUGIYAMA
-
Patent number: 7666985Abstract: HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.Type: GrantFiled: June 19, 2008Date of Patent: February 23, 2010Assignees: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu